Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
Related Articles
Urine electrooxidation for energy–saving hydrogen generation
Urea electrooxidation offers a cost-effective alternative to water oxidation for energy-saving hydrogen production. However, its practical application is limited by expensive urea reactants and sluggish reaction kinetics. Here, we present an efficient urine electrolysis system for hydrogen production, using cost-free urine as feedstock. Our system leverages a discovered Cl-mediated urea oxidation mechanism on Pt catalysts, where adsorbed Cl directly couple with urea to form N-chlorourea intermediates, which are then converted into N2 via intermolecular N–N coupling. This rapid mediated-oxidation process notably improves the activity and stability of urine electrolysis while avoiding Cl-induced corrosion, enabling over 200 hours of operation at reduced voltages. Accordingly, a notable reduction in the electricity consumption is achieved during urine electrolysis (4.05 kWh Nm−3) at 300 mA cm−2 in practical electrolyser for hydrogen production, outperforming the traditional urea (5.62 kWh Nm−3) and water (4.70–5.00 kWh Nm−3) electrolysis.
Golgi-restored vesicular replenishment retards bone aging and empowers aging bone regeneration
Healthy aging is a common goal for humanity and society, and one key to achieving it is the rejuvenation of senescent resident stem cells and empowerment of aging organ regeneration. However, the mechanistic understandings of stem cell senescence and the potential strategies to counteract it remain elusive. Here, we reveal that the aging bone microenvironment impairs the Golgi apparatus thus diminishing mesenchymal stem cell (MSC) function and regeneration. Interestingly, replenishment of cell aggregates-derived extracellular vesicles (CA-EVs) rescues Golgi dysfunction and empowers senescent MSCs through the Golgi regulatory protein Syntaxin 5. Importantly, in vivo administration of CA-EVs significantly enhanced the bone defect repair rate and improved bone mass in aging mice, suggesting their therapeutic value for treating age-related osteoporosis and promoting bone regeneration. Collectively, our findings provide insights into Golgi regulation in stem cell senescence and bone aging, which further highlight CA-EVs as a potential rejuvenative approach for aging bone regeneration.
Derivation of human toxicokinetic parameters and internal threshold of toxicological concern for tenuazonic acid through a human intervention trial and hierarchical Bayesian population modeling
Tenuazonic acid (TeA), a mycotoxin produced by Alternaria alternata, contaminates various food commodities and is known to cause acute and chronic health effects. However, the lack of human toxicokinetic (TK) data and the reliance on external exposure estimates have stalled a comprehensive risk assessment for TeA.
Young infants’ exposure to parabens: lotion use as a potential source of exposure
Parabens are widely used as antimicrobials in personal care products and pharmaceuticals. While previous studies demonstrate paraben exposure is ubiquitous, data investigating infants’ exposure is limited.
Long-term patient-reported outcomes following allogeneic hematopoietic cell transplantation
Therapeutic progress has improved the overall survival of patients treated with allogeneic hematopoietic cell transplantation (alloHCT). Thus, the impact on quality of life (QoL) becomes increasingly relevant. However, QoL is not monitored regularly in clinical practice, and most trials stop QoL assessments early post-alloHCT, missing long-term dynamics. To address this knowledge gap, we conducted a cross-sectional survey of 214 adult alloHCT recipients (average age 53 y, 42.5% female, median follow-up 56 months) to evaluate QoL using patient-reported outcome measurements (PROMs), spanning a period from 30 days to over 10 years post-transplant. Participants completed the EORTC QLQ-C30 and FACT-BMT at a single follow-up timepoint to investigate QoL-related factors. Comparing long-term follow-up patients (beyond year 3, n = 125) with short-term follow-up patients (day 30 to month 12, n = 89) shows significantly better long-term QoL outcomes (P = 0.016). However, PROM symptom scales indicate moderate fatigue and insomnia rates in long-term survivors. Better QoL was associated with male gender, lower ECOG, RIC conditioning, no relapse, no ongoing immunosuppression and full-time work. Summarized, while we observe encouraging long-term outcomes, our data suggest that QoL recovery remain highly individual. We strongly recommend the use of PROMs to enhance our understanding of long-term survivorship post-alloHCT.
Responses